- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
CHMP Grants Sandoz Positive Opinion for Proposed Infliximab Biosimilar
Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of biosimilar infliximab.
Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of its biosimilar infliximab.
The positive opinion is based on comprehensive data confirming the biosimilarity of infliximab to the reference product through analytical, preclinical, and clinical data that found the biosimilar matches the reference product in terms of quality, efficacy, and safety. CHMP has recommended the proposed biosimilar for the treatment of all indications of the reference product, including gastroenterology, rheumatology, and dermatology.
“Sandoz is proud to be at the forefront of diversifying the biologics treatment landscape by bringing biosimilar medicines to market for patients living with devastating autoimmune diseases. Today’s positive CHMP opinion marks a strong step forward in our efforts to accelerate patient access to biologics, and specifically infliximab, through our leading portfolio,” said Richard Francis, CEO of Sandoz, in a statement.
In the next step of the biosimilar approval process, the European Commission (EC) will review the CHMP’s positive opinion. The EC has the authority to approve or deny medicines for the European Union. If the EC approves the proposed biosimilar, it will grant a centralized marketing authorization that will be valid in the 28 EU member countries. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will follow corresponding decisions based on the EC’s recommendation.
Sandoz currently has 5 other biosimilars on the European market, including somatropin (sold as Omnitrope), epoetin alfa (sold as Binocrit), filgrastim (sold as Zarzio in Europe), etanercept (sold as Erelzi), and rituximab (sold as Rixathon). In addition, it has another 3 biosimilars in its pipeline: LA-EP2006, a proposed pegfilgrastim biosimilar for the treatment of chemotherapy induced neutropenia; GP2013, a proposed rituximab biosimilar currently approved in the EU and pending an FDA decision for the treatment of certain blood cancers and inflammatory diseases; and GP2017, a proposed adalimumab biosimilar to potentially treat autoimmune diseases, such as rheumatoid arthritis and psoriasis.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
